2024
Fever Prevention in Patients With Acute Vascular Brain Injury
Greer D, Helbok R, Badjatia N, Ko S, Guanci M, Sheth K, Diringer M, Mehta Y, Cava L, Hinduja A, Lele A, Sarwal A, Kulik T, Keller E, Smith G, Dennesen P, Dimitriadis K, Schonenberger S, Gunther A, Meisel A, Wolf S, Kollmar R, Barlinn K, Jeon S, Han M, Hong J, Lee R, Falcone G, Dashti S, Busl K, Ermak D, Berkeley J, Amory C, Swor R, DeGeorgia M, Green-LaRoche D, Thompson B, Hatton K, Sung G, Mehta C, Zurasky J, Da Silva I, James M, Aysenne A, Cervantes A, Devlin T, Chang I, Morris N, Venkatasubramanian C, Mushlschlegel S, Zachariah J, Chaudry F, Claassen J, Dangayach N, Choi H, Sadaka F, Miller C. Fever Prevention in Patients With Acute Vascular Brain Injury. JAMA 2024, 332: 1525-1534. PMID: 39320879, PMCID: PMC11425189, DOI: 10.1001/jama.2024.14745.Peer-Reviewed Original ResearchVascular brain injuryStandard care groupCare groupMajor adverse eventsPrimary outcomeStandard care patientsBlinded outcome assessmentIntensive care unit dischargeFunctional outcomesAdverse eventsBrain injuryFever preventionFever burdenPrincipal secondary end pointBetween-group differencesOpen-label randomized clinical trialPrevention groupFunctional recoveryPrincipal secondary outcomeCare patientsAssociated with worse outcomesMain OutcomesImpact functional outcomesSecondary end pointsTemperature management device
2023
Low‐Field Portable Magnetic Resonance Imaging for Post‐Thrombectomy Assessment of Ongoing Brain Injury
Sujijantarat N, Koo A, Jambor I, Malhotra A, Mazurek M, Parasuram N, Yadlapalli V, Chavva I, Lalwani D, Zabinska J, Roy J, Antonios J, Elsamadicy A, Renedo D, Hebert R, Schindler J, Gilmore E, Sansing L, de Havenon A, Olexa M, Schiff S, Iglesias J, Rosen M, Kimberly W, Petersen N, Sheth K, Matouk C. Low‐Field Portable Magnetic Resonance Imaging for Post‐Thrombectomy Assessment of Ongoing Brain Injury. Stroke Vascular And Interventional Neurology 2023, 3 DOI: 10.1161/svin.123.000921.Peer-Reviewed Original ResearchMechanical thrombectomyInterventional radiology suiteMagnetic resonance imagingRadiology suiteConventional MRIResonance imagingCerebral Infarction scoreOngoing brain injuryLarge vessel occlusionInfarct burdenRevascularization timeInfarct volumeClinical characteristicsInfarct progressionAdverse eventsIschemic changesMethods PatientsMedian timeBedside evaluationBrain injuryTimely imagingResults TwentyPatientsSubsequent imagingProcedural details
2019
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial
Selim M, Foster L, Moy C, Xi G, Hill M, Morgenstern L, Greenberg S, James M, Singh V, Clark W, Norton C, Palesch Y, Yeatts S, Investigators I, Dolan M, Yeh E, Sheth K, Kunze K, Muehlschlegel S, Nieto I, Claassen J, Falo C, Huang D, Beckwith A, Messe S, Yates M, O'Phelan K, Escobar A, Becker K, Tanzi P, Gonzales N, Tremont C, Venkatasubramanian C, Thiessen R, Save S, Verrault S, Collard K, DeGeorgia M, Cwiklinski V, Thompson B, Wasilewski L, Andrews C, Burfeind R, Torbey M, Hamed M, Butcher K, Sivakumar L, Varelas N, Mays-Wilson K, Leira E, Olalde H, Silliman S, Calhoun R, Dangayach N, Renvill R, Malhotra R, Kordesch K, Lord A, Calahan T, Geocadin R, Parish M, Frey J, Harrigan M, Leifer D, Mathias R, Schneck M, Bernier T, Gonzales-Arias S, Elysee J, Lopez G, Volgi J, Brown R, Jasak S, Phillips S, Jarrett J, Gomes J, McBride M, Aldrich F, Aldrich C, Kornbluth J, Bettle M, Goldstein J, Tirrell G, Shaw Q, Jonczak K. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Neurology 2019, 18: 428-438. PMID: 30898550, PMCID: PMC6494117, DOI: 10.1016/s1474-4422(19)30069-9.Peer-Reviewed Original ResearchConceptsBetter clinical outcomesPhase 2 trialSerious adverse eventsRankin Scale scorePlacebo groupIntracerebral hemorrhagePrimary outcomeClinical outcomesDay 90Deferoxamine mesylateModified intentionTreat populationAdverse eventsUS National InstitutesDouble-blind phase 2 trialScale scorePhase 3 efficacy trialsModified Rankin Scale scoreEfficacy of deferoxaminePhase 3 trialSupratentorial intracerebral hemorrhageAbsolute risk differenceProportion of participantsNational InstituteIron chelator deferoxamineEfficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial
Hanley D, Thompson R, Rosenblum M, Yenokyan G, Lane K, McBee N, Mayo S, Bistran-Hall A, Gandhi D, Mould W, Ullman N, Ali H, Carhuapoma J, Kase C, Lees K, Dawson J, Wilson A, Betz J, Sugar E, Hao Y, Avadhani R, Caron J, Harrigan M, Carlson A, Bulters D, LeDoux D, Huang J, Cobb C, Gupta G, Kitagawa R, Chicoine M, Patel H, Dodd R, Camarata P, Wolfe S, Stadnik A, Money P, Mitchell P, Sarabia R, Harnof S, Barzo P, Unterberg A, Teitelbaum J, Wang W, Anderson C, Mendelow A, Gregson B, Janis S, Vespa P, Ziai W, Zuccarello M, Awad I, Investigators M, Abdul-Rahim A, Abou-Hamden A, Abraham M, Ahmed A, Alba C, Aldrich E, Altschul D, Amin-Hanjani S, Anderson D, Ansari S, Antezana D, Ardelt A, Arikan F, Baguena M, Baker A, Barrer S, Becker K, Bergman T, Boström A, Braun J, Brindley P, Broaddus W, Brown R, Buki A, Cao B, Cao Y, Carrion-Penagos J, Chalela J, Chang T, Chorro I, Chowdhry S, Corral L, Csiba L, Davies J, Díaz A, Derdeyn C, Diringer M, Dlugash R, Ecker R, Economas T, Enriquez P, Ezer E, Fan Y, Feng H, Franz D, Freeman W, Fusco M, Galicich W, Gelea M, Goldstein J, Gonzalez A, Grabarits C, Greenberg S, Gress D, Gu E, Hall C, Hernandez F, Hoesch R, Hoh B, Houser J, Hu R, Huang Y, Hussain M, Insinga S, Jadhav A, Jaffe J, Jahromi B, Jallo J, James M, James R, Jankowitz B, Jeon E, Jichici D, Jonczak K, Jonker B, Karlen N, Keric N, Kerz T, Knopman J, Koenig C, Krishnamurthy S, Kumar A, Kureshi I, Laidlaw J, Lakhanpal A, Latorre J, Leifer D, Leiphart J, Lenington S, Li Y, Lopez G, Lovick D, Lumenta C, Luo J, Maas M, MacDonald J, MacKenzie L, Madan V, Majkowski R, Major O, Malhorta R, Malkoff M, Mangat H, Maswadeh A, Matouk C, McArthur K, McCaul S, Medow J, Mezey G, Mighty J, Miller D, Mohan K, Muir K, Muñoz L, Nakaji P, Nee A, Nekoovaght-Tak S, Nyquist P, O'Kane R, Okasha M, O'Kelly C, Ostapkovich N, Pandey A, Parry-Jones A, Perla K, Pollack A, Polster S, Pouratian N, Quinn T, Rajajee V, Reddy K, Rehman M, Reimer R, Rincon F, Rybinnik I, Sanchez B, Sansing L, Schneck M, Schuerer L, Schul D, Schweitzer J, Seder D, Seyfried D, Sheth K, Spiotta A, Stechison M, Szabo K, Tamayo G, Tanczos K, Taussky P, Terry J, Testai F, Thomas K, Thompson C, Thompson G, Torner J, Tran H, Tucker K, Ungar L, Varelas P, Vargas N, Vatter H, Venkatasubramanian C, Vermillion K, Vollmer D, Wang Y, Wang Y, Wen J, Whitworth L, Willis B, Wrencher M, Wright S, Xu Y, Yanase L, Yi X, Yu Z, Zomorodi A. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. The Lancet 2019, 393: 1021-1032. PMID: 30739747, PMCID: PMC6894906, DOI: 10.1016/s0140-6736(19)30195-3.Peer-Reviewed Original ResearchConceptsStandard medical care groupMedical care groupStandard medical carePhase 3 trialProportion of patientsSerious adverse eventsSupratentorial intracerebral hemorrhageCare groupIntracerebral hemorrhageMedical careAdverse eventsMRS scoreFunctional outcomeComputer-generated number sequenceModified Rankin Scale scoreInvasive catheter evacuationPrespecified baseline covariatesPrimary efficacy outcomeLarge intracerebral hemorrhageGood functional outcomeRankin Scale scoreNumber of patientsIntracerebral hemorrhage evacuationLogistic regression modelsBlinded endpoint
2016
Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial
Sheth KN, Elm JJ, Molyneaux BJ, Hinson H, Beslow LA, Sze GK, Ostwaldt AC, del Zoppo GJ, Simard JM, Jacobson S, Kimberly WT. Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology 2016, 15: 1160-1169. PMID: 27567243, DOI: 10.1016/s1474-4422(16)30196-x.Peer-Reviewed Original ResearchConceptsPlacebo-controlled phase 2 trialIntravenous glyburideLarge hemispheric infarctionPhase 2 trialGlyburide groupHemispheric infarctionDecompressive craniectomyPlacebo groupBrain swellingModified Rankin Scale scoreProtocol study populationWeb-based randomisationComposite primary outcomePrimary efficacy outcomeSerious adverse eventsProportion of patientsRankin Scale scoreBolus intravenous injectionLarge hemispheric strokePotential clinical benefitEfficacy outcomesStudy drugAdverse eventsCardiac eventsCerebral edema
2013
Pilot Study of Intravenous Glyburide in Patients With a Large Ischemic Stroke
Sheth KN, Kimberly WT, Elm JJ, Kent TA, Mandava P, Yoo AJ, Thomalla G, Campbell B, Donnan GA, Davis SM, Albers GW, Jacobson S, Simard JM, Stern BJ. Pilot Study of Intravenous Glyburide in Patients With a Large Ischemic Stroke. Stroke 2013, 45: 281-283. PMID: 24193798, PMCID: PMC4235339, DOI: 10.1161/strokeaha.113.003352.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overBlood GlucoseBrain EdemaBrain IschemiaComorbidityFemaleFibrinolytic AgentsGlyburideHumansHypoglycemiaHypoglycemic AgentsInjections, IntravenousMagnetic Resonance ImagingMaleMiddle AgedPatient SafetyPilot ProjectsProspective StudiesStrokeTissue Plasminogen ActivatorTreatment OutcomeWhite PeopleYoung AdultConceptsIschemic strokeLesion volumeIntravenous recombinant tissue-type plasminogen activatorRecombinant tissue-type plasminogen activatorIpsilateral hemisphere volumeLarge ischemic strokeSerious adverse eventsAcute ischemic strokeRetrospective clinical dataFeasibility of recruitingTissue-type plasminogen activatorIntravenous glyburideSevere strokeSymptomatic hypoglycemiaAdverse eventsFocal ischemiaMean ageClinical trialsHemisphere volumeClinical dataDose reductionAge 18PatientsSulfonylurea receptorPlasminogen activator